Correction to: *Scientific Reports* 10.1038/s41598-018-27960-7, published online 29 June 2018

This Article contains errors.

In Table 1, the formatting for the header "Recipient characteristics" is incorrect. The correct Table [1](#Tab1){ref-type="table"} appears below:Table 1Donor and recipient characteristics with Log-rank test p-value for qualitative variables and quantitative variables across risk groups when significant threshold was met.Donor characteristicsMean survival (sd)P-valueSex (%):0.37   Male55.014.55 (0.05)   Female44.994.56 (0.08)Cause of death (%):**\<0.01**   Cerebrovascular accident60.294.44 (0.05)   Trauma24.644.69 (0.07)   Anoxia12.024.80 (0.11)   Other3.054.72 (0.21)Diabetes (%):0.98   yes7.754.56 (0.14)   no92.254.56 (0.04)ABO group (%):0.22   A44.584.57 (0.06)   B9.874.72 (0.12)   O41.934.49 (0.06)   AB3.614.78 (0.19)Hypertension (%):0.21   yes35.704.49 (0.07)   no64.304.60 (0.05)Malignancy (%):0.43   yes1.894.72 (0.26)   no98.114.49 (0.04)Alcohol (%):0.53   yes15.024.50 (0.10)   no84.984.57 (0.04)Smoking (%):0.47   yes37.594.59 (0.06)   no62.414.53 (0.05)Drugs (%):0.52   yes4.174.65 (0.19)   no95.834.56 (0.04)Hepatitis C virus antibody (%):0.46   +0.454.09 (0.56)   −99.554.53 (0.04)Hepatitis B core antibody (%):0.62   +4.394.61 (0.18)   −95.614.53 (0.04)Inotropes (dobutamine, dopamine, noradrenaline, epinephrine) (%):0.72   yes39.164.57 (0.06)   no60.844.55 (0.05)Liver type (%):0.44   Partial/split5.104.43 (0.17)   Total94.904.55 (0.04)Age (%):**\<0.001**   ≤6976.474.64 (0.04)   \>6923.534.27 (0.09)Height (%):**0.07**   \<16222.624.42 (0.08)   ≥16277.384.60 (0.04)Weight, mean (sd)72.88 (15.17)BMI, mean (sd)25.33 (4.62)Sodium: latest (mmol/L) (%):**0.04**   136--14643.854.47(0.06)   other56.154.63(0.05)Sodium: highest (mmol/L), median (range)149 (120-180)MDRD creatinine clearance: latest (ml/min/1.73 m^*2*^) (%):**0.01**   \<6025.304.38 50.08)   60--8929.514.55 (0.07)   ≥9045.194.66 (0.06)MDRD creatinine clearance: lowest (ml/min/1.73 m^*2*^) (%):**0.01**   \<6035.354.41 (0.07)   60--8936.834.61 (0.06)   ≥9027.824.68 (0.07)Aspartate aminotransferase: latest (U/L), median (range)39 (0--2000)Aspartate aminotransferase: highest (U/L), median (range)51 (9--2000)Alanine transaminase: latest (U/L) (%):**0.04**   7--4167.334.50 (0.05)   other32.674.67 (0.07)Alanine transaminase: highest (U/L), median (range)33 (1--2000)Total bilirubin: latest (µmol/L), median (range)10 (0--150)Total bilirubin: highest (µmol/L), median (range)12 (1--150)Alkaline phosphatases: latest (U/L) (%):**0.06**   \<334.444.26 (0.19)   33--9676.124.54 (0.04)   \>9619.444.71 (0.08)Alkaline phosphatases: highest (U/L) (%):**0.09**   \<331.784.22 (0.31)   33--9672.224.51 (0.05)   \>9626.004.67 (0.07)Gamma glutamyl transpeptidase: latest (U/L), median (range)30 (0--1477)Gamma glutamyl transpeptidase: highest (U/L), median (range)36 (1--1835)Intensive care unit stay (in days) (%):**\<0.001**   ≤479.684.48 (0.04)   \>429.324.83 (0.08)Estimated distance between donor and recipient location (minutes) (%):**\<0.01**   \<1522.604.77 (0.08)   ≥1577.404.50 (0.04)"Hors tour" (%):0.84   yes6.084.57 (0.16)   no93.924.55 (0.04)Donor risk index, mean (sd)1.65 (0.40)------Eurotransplant donor risk index, mean (sd)1.63 (0.36)------UK Donor Liver Index, mean (sd)1.15 (0.26)------**Recipient characteristicsMean survival (sd)P-value**Sex (%):0.91   Male73.544.55 (0.05)   Female26.464.56 (0.08)Cancer (%):0.29   yes29.004.62 (0.07)   no71.004.53 (0.05)Decompensated cirrhosis (%):**\<0.001**   yes37.744.73 (0.06)   no62.264.46 (0.05)Non-cirrhotic liver disease (%):0.63   yes1.414.63 (0.30)   no98.594.48 (0.04)Emergency (%):**\<0.001**   yes6.723.78 (0.17)   no93.284.58 (0.04)MELD exception (%):0.36   yes18.004.45 (0.09)   no82.004.57 (0.04)Previous transplantation (%):**\<0.001**   yes8.583.76 (0.15)   no91.424.60 (0.04)On dialysis (%):**\<0.001**   yes5.333.43 (0.19)   no94.674.58 (0.04)Medical condition before LT (%):**\<0.001**Intensive care unit17.703.88 (0.11)Hospital (no intensive care unit)13.884.60 (0.10)Not hospitalized68.424.71 (0.04)Hepatitis B core antibody (%):0.73   +20.054.53 (0.09)   −79.954.56 (0.04)Hepatitis C virus antibody (%):**\<0.001**   +23.834.23 (0.08)   −76.174.66 (0.04)Diabetes (%):**0.06**   yes22.674.42 (0.08)   no77.334.60 (0.04)Encephalopathy (%):**\<0.001**   grade 168.144.62 (0.05)   grade 224.844.52 (0.08)   grade 37.023.95 (0.17)ABO group (%):0.80   A45.444.56 (0.06)   B11.164.63 (0.11)   O39.034.55 (0.06)   AB4.374.43 (0.19)Age, mean (sd)53.24 (10.39)Body mass index (%):**0.20**   \<18.53.564.35 (0.21)   18.5--2544.694.50 (0.06)   ≥2551.754.62 (0.05)Model for end stage liver disease before LT (%):**\<0.001**   \<2972.734.65 (0.04)   ≥2927.274.32 (0.08)Waiting time (in days) (%):**\<0.001**   \<2124.544.34 (0.08)   ≥2175.464.63 (0.04)Follow-up (years), mean (sd)2.33 (1.63)

In addition, Table 2 contains formatting errors. The correct Table [2](#Tab2){ref-type="table"} appears below:Table 2Retained covariates in the different selection way.CovariatesModel 1Model 2Model 3Final modelDonor**Age**××××**Cause of death**××××**Intensive care unit stay**××××ABO group×× (adjustment)MDRD creatinine clearance: lowest××Partial/split liver××Alcohol×Alkanine phosphatases: latest×Estimated distance×Recipient**Re-transplantation**××××**On dialysis**××××**Medical condition before LT**××××**Hepatitis C virus antibody**××××**Diabetes**××××**Decompensated cirrhosis**××××MELD exception××ABO group××PerfomancesC-index0.626(0.009)0.616(0.009)0.616(0.009)0.625(0.009)K statistic0.617(0.007)0.611(0.008)0.610(0.008)0.616(0.007)$\documentclass[12pt]{minimal}
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                \begin{document}$${R}_{D}^{2}$$\end{document}$0.518(0.020)0.492(0.021)0.492(0.021)0.516(0.021)Covariates in bold are those which appeared in the three selection models. Model 1: A complete model with selection according to the Akaiké criterion; Model 2: (1) log rank tests with a threshold of 20%, (2) multivariate model included the selected covariates with a selection threshold set at 20%; Model 3: (1) log rank tests with a threshold of 20%, (2) two multivariate models for donor and recipient with the selected covariates with a selection threshold set at 20%, (3) multivariate model with all the covariates selected with a selection threshold set at 20%. The retained full model included all the variables present in at least two of the three models and the set of covariates retained in addition.

Finally, there are errors in Table 5, where the formatting of the "Donor characteristics" header is incorrect. Additionally, the word "Hospital" is incorrectly given as "Hosptial" and the P-values for "ICU stay (in days)" and "Clearance MDRD: lowest (ml/min/1.73 m2)" are omitted. The correct Table 5 appears below as Table [3](#Tab3){ref-type="table"}:Table 3Differences in donor and recipient characteristics between the derivation and validation datasets (P-values, $\documentclass[12pt]{minimal}
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                \begin{document}$${\chi }^{2}$$\end{document}$ tests and ANOVA when appropriate).Recipient characteristics2009--2013 (n = 3961)2014 (n = 1048)P- valuesExpert component (no)3248 (82%)874 (83.4%)0.31ABO group0.59   A1800 (45.44%)465 (44.37%)   AB173 (4.37%)38 (3.63%)   B442 (11.16%)118 (11.26%)   O1546 (39.03%)427 (40.74%)Re-transplantation (no)3621 (91.42%)961 (91.7%)0.82On dialysis (no)3750 (94.67%)987 (94.18%)0.58Medical condition before LT0.45   Home2710 (68.42%)705 (67.27%)   Hospital550 (13.89%)140 (13.36%)   ICU701 (17.7%)203 (19.37%)Hepatitis C virus antibody (−)3017 (76.17%)811 (77.39%)0.43Diabetes (no)3063 (77.33%)793 (75.67%)0.27Decompensated cirrhosis (no)2466 (62.26%)667 (63.65%)0.43**Donor characteristics2009--2013 (n = 3961)2014 (n = 1048)P-values**ABO group0.75   A1766 (44.58%)460 (43.89%)   AB143 (3.61%)32 (3.05%)   B391 (9.87%)102 (9.73%)   O1661 (41.93%)454 (43.32%)Age**\<0.01**   ≤693029 (76.47%)710 (67.75%)   \>69932 (23.53%)338 (32.25%)COD**\<0.01**   Anoxia476 (12.02%)150 (14.31%)   CVA2388 (60.29%)651 (62.12%)   Trauma976 (24.64%)231 (22.04%)   Other121 (3.05%)16 (1.53%)ICU stay (in days)0.23   ≤43156 (79.68%)853 (81.39%)   \>4805 (20.32%)195 (18.61%)Clearance MDRD: lowest (ml/min/1.73 m^*2*^)0.55   \<601400 (35.34%)385 (36.74%)   60--891459 (36.83%)388 (37.02%)   ≥901102 (27.82%)275 (26.24%)Liver type (entire)3759 (94.9%)1007 (96.09%)0.13
